Carcinoid tumors are part of a heterogeneous group of gastrointestinal and pancreatic endocrine tumors that are characterized by their capacity to produce and secrete hormones, 5-hydroxytryptamine ...

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal ...

Background. A 48-year-old man presented with diarrhea, flushing, abdominal pain and weight loss of 10 kg over a 6-month period. He subsequently developed dyspnea on exertion. Diagnosis. Carcinoid ...

our doctors are working to improve the understanding and treatment of neuroendocrine tumors of the gastrointestinal system. Neuroendocrine tumors act quite differently — and, as a result, are managed ...

Jennifer Chan, MD, MPH, discussed the recent FDA approval of cabozantinib in pancreatic and extrapancreatic neuroendocrine tumors.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

Jennifer Chan, MD, MPH, discussed the findings from the phase 3 CABINET trial leading to the FDA approval of cabozantinib in patients with neuroendocrine tumors.

This significant leap is attributed to rising incidences of carcinoid tumors, especially in the lungs and gastrointestinal tract, matched with an increase in the development and utilization of ...

– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...